Loading
A phase 2 trial of Olaparib, Durvalumab in ovarian cancer, run by AGO Research GmbH, now recruiting.
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC is a phase 2 interventional study registered as NCT04644289 by AGO Research GmbH, with 60 participants planned, started 2022-05-05 and due to reach its primary completion in 2028-01. Interventions recorded: olaparib, durvalumab. Conditions listed: Epithelial Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/